



Pharmacy Quality Assurance Commission
PO Box 47852 Olympia, WA 98504
www.doh.wa.gov · TDD Relay: 711

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.

January 31, 2025 Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.
Location: Zoom ID: **890 1330 6617**
<https://us02web.zoom.us/j/89013306617>
Or One tap mobile :
+12532050468,,89013306617# US
+12532158782,,89013306617# US (Tacoma)
<https://zoom.us/join>
Webinar ID: 890 1330 6617
In Person: Department of Health, TC2
[111 Israel Rd SE, Rm. 140](#)
[Tumwater, WA 98501](#)
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058
Joshua.Munroe@doh.wa.gov
Commission Office: wspqac@doh.wa.gov

No registration needed. **All attendees will join the call with their audio connection muted.**

12:00 p.m.

1. Call to Order
 - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

1:00 PM (approximately)
Meeting Adjourned

[Link to Washington State Legislature Bill Information 2025](#)

Monday, January 13 – First day of session
 Friday, February 21 – Policy committee cutoff **Next cutoff**
 Friday, February 28 – Fiscal committee cutoff
 Wednesday, March 12 – House of origin cutoff
 Wednesday, April 2 – Policy committee cutoff (opposite house)

Tuesday, April 8 – Fiscal committee cutoff (opposite house)
 Wednesday, April 16 – Opposite house cutoff
 Sunday, April 27 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1520	Pharmacists' scope of practice	<p>The bill would add a new section to chapter 18.64 RCW that allows pharmacists to prescribe certain categories of drugs including immunizations, antihistamine agents, hormonal contraception, and other medications used for the treatment of diseases, as well as drugs, drug categories, or devices that are limited to specified circumstances such as not requiring a new diagnosis or being minor and generally self-limiting in nature. The new section also has an expiration date of January 1, 2030.</p> <p>The definition for “practice of pharmacy” in RCW 18.64.011(32) is amended to include the diagnosing of conditions and diseases and the prescribing or ordering of drugs and devices as authorized by chapter 18.64 RCW and commission rules. The commission is also granted rulemaking authority to administer and implement the bill.</p> <p>RCW 69.41.030 is also amended to allow pharmacists to sell or deliver legend drugs “to the extent permitted under chapter 18.64 RCW” and removing the requirement to do so only through the creation and approval of “written guidelines or protocols” under RCW 18.64.011 and approved by a practitioner authorized to prescribe drugs.</p>	<p>HB 1520 <i>Sponsor(s):</i> Representatives Thai, Reed, Simmons, and Macri</p> <p><i>First Reading (House):</i> 1/22/2025, referred to Health Care & Wellness Committee.</p>
SB 5513	Pharmacists' scope of practice	Companion bill to HB 1520.	SB 5513

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>Sponsor(s)</i>: Senators Slatter, Chapman, Nobles, and Short</p> <p><i>First Reading (Senate)</i>: 1/27/2025, referred to Health & Long-Term Care Committee.</p>
HB 1009	Membership of the Pharmacy Quality Assurance Commission	<p>HB 1009 amends RCW 18.64.001 pertaining to individual eligibility to apply for a seat on the Pharmacy Quality Assurance Commission (commission). The bill changes one of the seats reserved only for a licensed pharmacist to allow for a public member who “may be an owner, officer, or operator of a pharmacy, but may not be licensed as a pharmacist or pharmacy technician” to also apply for the seat.</p>	<p><u>HB 1009</u></p> <p><i>Sponsor(s)</i>: Representatives Low, Ramel, and Eslick</p> <p><i>Executive Session (Health Care & Wellness)</i>: 1/17/2025; passed through committee with a DO PASS recommendation; referred to Rules 2 Review (1/20)</p> <p><i>Second Reading (Rules)</i>: 1/28/2025; Rules Committee relieved of further consideration and placed on second reading</p>
SB 5019	Prepackaged medication distribution	<p>RCW 70.41.480(3) creates restrictions for a practitioner or registered nurse to distribute prepackaged emergency medications to patients upon discharge from an emergency department. Effective January 1, 2025, these restrictions include no more than a 48-hour supply that can be dispensed to a patient except when:</p> <ul style="list-style-type: none"> • community or hospital pharmacy services will not be available within 48 hours; or • human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs or therapies are required. 	<p><u>SB 5019</u></p> <p><i>Sponsor(s)</i>: Senators Chapman, Bateman, Christian, Dhingra, Harris, Riccelli, Saldaña, Slatter, and Wellman</p> <p><i>Pre-filed</i>: 12/9/2024</p> <p><i>First Reading (Senate)</i>: 1/13/2025, referred to Health & Long-Term Care Committee.</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		<p>SB 5019 amends these exceptions to include when anti-infective drugs or therapies are required or when drugs are packaged directly by the manufacturer in quantities larger than 48 hours, in addition to the above list.</p> <p>The bill also amends RCW 18.64.450 to allow health care entities (HCEs) to dispense and deliver legend drugs and controlled substances beyond the 72-hour limit in the following situations:</p> <ul style="list-style-type: none"> • Community or hospital outpatient pharmacy services will not be available within 72 hours; • Anti-infectives or human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs; or • Drugs or therapies packaged directly by the manufacturer for a period longer than a 72-hour period. 	<p><i>Public Hearing (Health & Long-Term Care): 1/23/2025</i></p>
HB 1186	Prepackaged medication distribution	Companion bill to SB 5019.	<p>HB 1186 <i>Sponsor(s):</i> Representatives Parshley, Rule, Low, Reed, Ramel, Macri, Obras, Farivar, Doglio, Fosse, Ormsby, Salahuddin, Bernbaum, and Hill</p> <p><i>Pre-filed:</i> 1/7/2025 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee. <i>Public Hearing (Health Care & Wellness):</i> 1/24/2025 <i>Executive Session (Health Care & Wellness):</i> 1/31/2025</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1124	Psychologist prescriptive authority certification	HB 1124 amends chapter 18.83 RCW to establish a certification for prescribing psychologists. The bill authorizes prescribing psychologists to prescribe, administer, discontinue, and distribute controlled substances to treat mental illnesses. The bill also amends the definition of practitioner in RCW 18.64.011 to include prescribing psychologists.	<p>HB 1124 <i>Sponsor(s):</i> Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Pre-filed:</i> 12/23/2024 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee.</p>
SB 5201	Access to psychedelic substances	<p>This bill establishes wellness model-based psilocybin services and establishes DOH and LCB authority to license, regulate, and enforce all provisions. Psilocybin can only be administered to a person 21 years of age or older in an approved setting, under the supervision of a licensed psilocybin facilitator or clinical facilitator. The program development period is designated from September 1, 2025 to September 1, 2027, during which DOH is to establish a Psychedelic Substances Board to advise DOH, conduct rulemaking, and establish educational trainings and exams.</p> <p>DOH must establish rules regarding qualifications, licensing and renewals, fees, education and training, substantially equivalent qualifications, testing, scope of practice, and other regulations specified in the bill for multiple new professions and facilities. DOH must also establish rules for defining “approved supervisor” qualification requirements, authorized disclosure of protected client information, and other requirements outlined in the bill. Rules must be adopted and forms established by October 31, 2027. DOH must begin receiving applications November 1, 2027.</p> <p>“Psychedelic substance” is defined as psilocybin until the end of 2029.</p>	<p>SB 5201 <i>Sponsor(s):</i> Senators Salomon, Nobles, Bateman, Trudeau, Lovelett, Frame, Chapman, Hasegawa, Wellman, Holy, King, Saldaña, Schoesler, and J. Wilson</p> <p><i>Pre-filed:</i> 1/9/2025 <i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee.</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1433	Access to psychedelic substances	Companion bill to SB 5201.	<p>HB 1124 <i>Sponsor(s):</i> Representatives Macri, Couture, Ramel, Griffey, Lekanoff, Ormsby, Nance, Walen, Cortes, Fosse, Doglio, Reeves, Goodman, McEntire, Bernbaum, Waters, Street, Pollet, Gregerson, Rude, Simmons, Berry, Fitzgibbon, Parshley, Peterson, Reed, Farivar, Tharinger, and Hill</p> <p><i>First Reading (House):</i> 1/20/2025, referred to Health Care & Wellness Committee.</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1422	Modifying the drug take-back program	<p>This bill amends various statutes in chapters 69.48 and 43.131 RCW relating to the drug take-back (i.e. safe medication return program) program. The bill expands the number of required elements that a program operator must submit via report to the department and updates the evaluation and approval standards for such reports.</p> <p>The bill further updates enforcement mechanisms if a program operator is out of compliance and allows the department to set an annual operating fee.</p>	<p>HB 1422 <i>Sponsor(s):</i> Representatives Peterson, Davis, Thai, Ormsby, Hill, Macri, and Timmons</p> <p><i>First Reading (House):</i> 1/20/2025, referred to Health Care & Wellness Committee.</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		A new section is also created in chapter 69.48 RCW to further outline the duties and responsibilities of a drug take-back program operator.	
SB 5051	Consolidating regulatory authority for nursing assistants	This bill amends sections in chapters 18.79 and 18.88A RCW to consolidate the regulatory authority of nursing assistants under the Board of Nursing's jurisdiction.	<p><u>SB 5051</u> <i>Sponsor(s):</i> Senators Bateman, Riccelli, Cleveland, Nobles, and Wellman</p> <p><i>Public Hearing (Health & Long-Term Care):</i> 1/21/2025 <i>Executive Session (Health & Long-Term Care):</i> 1/24/2025; majority voted for DO PASS recommendation <i>Second Reading (Rules):</i> 1/27/2025</p>
SB 5228	Governor's interagency coordinating council on health disparities updates	<p>This bill amends sections in chapter 43.20 RCW to update the description and composure of the coordinating council. Aside from updating definitions and making technical and grammatical fixes, the bill also amends RCW 43.20.275 to raise the number of seats to 24, including additional seats for public members and commission/committees such as the commission on African American affairs and the Governor's Committee on Disability Issues and Employment.</p> <p>RCW 43.20.280 is further amended to update the vision and goals of the council, public hearing and research requirements, and a deadline for the council's official report to the governor.</p>	<p><u>SB 5228</u> <i>Sponsor(s):</i> Senators Riccelli, Hasegawa, Conway, Nobles, and C. Wilson</p> <p><i>Pre-filed:</i> 1/10/2025 <i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee. <i>Public Hearing (Health & Long-Term Care):</i> 1/24/2025</p>
SB 5244	WIC program staff exemptions for hematological screening tests	This bill adds a subsection to RCW 18.360.090 to include hematological tests and evaluations conducted by persons working at a special supplemental nutrition program for women, infants, and children (WIC) as exempt from other prohibitions or restrictions in chapter 18.360 RCW.	<p><u>SB 5244</u> <i>Sponsor(s):</i> Senators Riccelli, Bateman, Nobles, Saldaña, and C. Wilson</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>First Reading (Senate): 1/14/2025, referred to Health & Long-Term Care Committee.</i></p> <p><i>Public Hearing (Health & Long-Term Care): 1/23/2025</i></p> <p><i>Executive Session (Health & Long-Term Care): 1/24/2025; majority voted for DO PASS recommendation</i></p> <p><i>Second Reading (Rules): 1/27/2025</i></p>

Additional Bills to Watch			
Bill # /Companion	Short Title		Committee Action (subject to change)
<u>HB 1034</u>	Nonopioid drugs for the treatment of pain	<u>HB 1034</u> <i>Sponsor(s): Representatives Ortiz-Self, Peterson, Simmons, Kloba, Ormsby, Lekanoff, Donaghy, and Hill</i> <i>Pre-filed: 12/11/2024</i> <i>First Reading (House): 1/13/2025, referred to Health Care & Wellness Committee.</i> <i>Public Hearing (Health Care & Wellness): 1/21/2025</i>	
<u>HB 1209</u>	Transfer of sodium nitrite	<u>HB 1209</u> <i>Sponsor(s): Representatives Mena, Walen, Reed, Ryu, Berry, Alvarado, Macri, Farivar, Doglio, Pollet, Ormsby, Salahuddin, and Hill</i> <i>Public Hearing (Consumer Protection & Business): 1/17/2025</i> <i>Executive Session (Consumer Protection & Business): 1/22/2025; no action taken</i>	

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Second Executive Session (Consumer Protection & Business): 1/28/2025</i>
SB 5178	Transfer of sodium nitrite	<u>SB 5178</u> <i>Sponsor(s):</i> Senators Trudeau, Harris, Frame, Hasegawa, Lias, Nobles, Orwall, Pedersen, Salomon, and Shewmake <i>Executive Session (Health & Long-Term Care): 1/17/2025</i> <i>Finance Committee Recommendation: 1/20/2025, referred to Business, Financial Services & Trade Committee.</i> <i>Public Hearing (Business, Financial Services & Trade): 1/30/2025</i>
SB 5242	Interactive screening program for behavioral health service access	<u>SB 5242</u> <i>Sponsor(s):</i> Senators Orwall, Harris, Hasegawa, Krishnadasan, Nobles, Shewmake, Valdez, and C. Wilson <i>First Reading (Senate): 1/14/2025, referred to Health & Long-Term Care Committee.</i> <i>Public Hearing (Health & Long-Term Care): 1/28/2025</i>
SB 5387	Corporate practice of medicine	<u>SB 5387</u> <i>Sponsor(s):</i> Senators Robinson, Hasegawa, Lias, Nobles, Riccelli, Stanford, and Valdez <i>First Reading (Senate): 1/21/2025, referred to Health & Long-Term Care Committee.</i>
HB 1675	Corporate practice of medicine	<u>HB 1675</u> <i>Sponsor(s):</i> Representative Thai <i>First Reading (House): 1/28/2025, referred to Health Care & Wellness Committee.</i>
SB 5452	Licensing psychiatric pharmacists as agency-affiliated counselors	<u>SB 5452</u> <i>Sponsor(s):</i> Senators Slatter and Nobles <i>First Reading (Senate): 1/23/2025, referred to Health & Long-Term Care Committee.</i>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary